,i #aahth ,,congress #ast ,session ,h4 ,r4 #acic ,,in ,,the ,,house ,,of ,,representatives ,march #g1 #bjbc,ms4 ,dean of ,pennsylvania 7for herself and ,ms4 ,mace7 introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce1 and in addition to the ,committee on the ,judiciary1 for a period to be subsequently determined by the ,speaker1 in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned ,a ,,bill ,to amend the ,controlled ,substances ,act to define currently accepted medical use with severe restrictions1 and for other purposes4 #a4 ,currently accepted medical use with severe restrictions 7a7 ,definitions ,section #ajb of the ,controlled ,substances ,act 7#ba ,u4,s4,c4 #hjb7 is amended-- 7#a7 by redesignating paragraph 7#eh7 7defining a serious violent felony7 as paragraph 7#ei72 7#b7 by redesignating the second paragraph 7#eg7 7defining a serious drug felony7 as paragraph 7#eh72 and 7#c7 by adding at the end the following3 7#fj7 7,a7 ,subject to subparagraph 7,b71 the term currently accepted medical use with severe restrictions1 with respect to a drug or other substance1 includes a drug or other substance that is an active metabolite1 moiety1 or ingredient 7whether in natural or synthetic form7 of an investigational new drug for which a waiver is in effect under section #eje7;i7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee7;i77 or section #cea7;a77#c7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bfb7;a77#c77 and that the ,secretary-- 7i7 designates as a breakthrough therapy under section #ejf7;a7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cef7;a772 or 7ii7 authorizes for expanded access under subsection 7b7 or 7c7 of section #efa of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cfj;bbb71 either alone or as part of a therapeutic protocol1 to treat patients with serious or life-threatening diseases for which no comparable or satisfactory therapies are available4 7,b7 ,a drug or other substance shall not be treated as meeting the criteria under subparagraph 7,a7 for having a currently accepted medical use with severe restrictions if-- 7i7 in the case of a drug or other substance described in subparagraph 7,a77ii7-- 7,i7 the ,secretary places the expanded access or protocol for such drug on clinical hold as described in section #cab4db of title #ba1 ,code of ,federal ,regulations 7or any successor regulations72 7,,ii7 there is no other investigational new drug containing the drug or other substance for which expanded access has been authorized under section #efa7;a7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cfj;bbb7a772 and 7,,iii7 the drug or other substance does not meet the requirements of subparagraph 7,a77i72 or 7ii7 the drug or other substance is approved under section #eje of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee7 or section #cea of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bfb74 4 7b7 ,authority and criteria for classification of substances ,section #bja7;j7 of the ,controlled ,substances ,act 7#ba ,u4,s4,c4 #haa7;j77 is amended-- 7#a7 in paragraph 7#a71 by inserting a drug designated as a breakthrough therapy under section #ejf7;a7 of the ,food ,drug and ,cosmetic ,act 7#ba ,u4,s4,c4 #cef7;a771 or a drug authorized for expanded access under subsection 7b7 or 7c7 of section #efa of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cfj;bbb71 after subsection 7f712 7#b7 in paragraph 7#b7-- 7,a7 in subparagraph 7,a71 by striking 2 or and inserting a semicolon2 7,b7 in subparagraph 7,b71 by striking the period at the end and inserting a semicolon2 and 7,c7 by adding at the end the following3 7,c7 the date on which the ,attorney ,general receives notification from the ,secretary of ,health and ,human ,services that the ,secretary has designated the drug as a breakthrough therapy under section #ejf7;a7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cef7;a77 or authorized the drug for expanded access under subsection 7b7 or 7c7 of section #efa of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cfj;bbb72 or 7,d7 the date on which the ,attorney ,general receives any written notification demonstrating that the ,secretary1 before the date of enactment of this subparagraph1 designated the drug as a breakthrough therapy under section #ejf7;a7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cef7;a77 or authorized the drug for expanded access under subsection 7b7 or 7c7 of section #efa of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cfj;bbb74 2 7#c7 in paragraph 7#c71 by inserting or paragraph 7#d7 after paragraph 7#a72 and 7#d7 by adding at the end the following3 7#d7 ,with respect to a drug moved from schedule ,i to schedule ,,ii pursuant to paragraph 7#a7 and the expedited procedures described under this subsection1 if the drug no longer has a currently accepted medical use with severe restrictions and the ,secretary of ,health and ,human ,services recommends that the ,attorney ,general control the drug in schedule ,i pursuant to subsections 7a7 and 7b71 the ,attorney ,general shall1 not later than #ij days after receiving written notification from the ,secretary1 issue an interim final rule controlling the drug in accordance with such subsections and section #bjb7;b7 using the procedures described in paragraph 7#c7 of this subsection4 4